On this page
CUPRIC CHLORIDE
Overview
Active ingredients
Source: NDC Directory| Ingredient | Strength | RxCUI | Monograph |
|---|---|---|---|
| Cupric Chloride | .4 mg/mL | 204536 | — |
Forms, strengths and routes
Source: NDC DirectoryRegulatory status
Source: Drugs@FDANDC Directory| Product | Trade name | Form | Strength | Ingredient | Status | TE | Flags |
|---|---|---|---|---|---|---|---|
| 217626-001 | CUPRIC CHLORIDE | INJECTABLE | CUPRIC CHLORIDE | Prescription | AP |
Therapeutic equivalence
Source: Orange BookWhat this rating means: Therapeutically equivalent — bioequivalence demonstrated (parenteral aqueous solutions)
Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.
Approval history
Source: Drugs@FDA| Type | No. | Action | Status | Date | Review |
|---|---|---|---|---|---|
| Original application | 1 | Approved | April 30, 2024 | Standard |
Prescribing information
Source: openFDA Drug LabelingReproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20260204). This is the manufacturer's labelling text, not a summary and not advice.
Indications and Usage
openFDA Drug LabelingINDICATIONS AND USAGE Cupric Chloride Injection, USP 0.4 mg/mL is indicated for use as a supplement to intravenous solutions given for total parenteral nutrition (TPN). Administration helps to maintain copper serum levels and to prevent depletion of endogenous stores and subsequent deficiency symptoms.
Dosage and Administration
openFDA Drug LabelingDOSAGE AND ADMINISTRATION Cupric chloride injection contains 0.4 mg of copper/mL and is administered intravenously only after dilution. The additive should be diluted in a volume of fluid not less than 100 mL. For the adult receiving TPN, the suggested additive dosage of copper is 0.3 mg/day to 0.5 mg/day. For pediatric patients, the suggested additive dosage of copper is 20 mcg/kg/day (0.05 mL/kg/day) up to a maximum of 500 mcg/day. This product is not appropriate for patients weighing less than 4 kg due to the inability to measure the appropriate amount of the product. Do not administer cupric chloride injection intramuscularly because the acidic pH of the solution may cause considerable tissue irritation. Cupric chloride injection should only be used in conjunction with a pharmacy directed admixture program using aseptic technique in a laminar flow environment; it should be used promptly and in a single operation without any repeated penetrations. The solution contains no preservatives; discard the unused portion immediately after the admixture procedure is completed. Cupric chloride injection should be inspected visually for particulate matter and discoloration prior to administration. Do not use unless the solution is clear and the seal is intact. Cupric ion may degrade ascorbic acid in TPN solutions. In order to avoid this loss of ascorbate, multivitamin additives should be added to TPN solutions immediately prior to infusion. Alternatively, the multivitamin additive may be added to one container of TPN solution, followed by copper in a subsequent container.
Contraindications
openFDA Drug LabelingCONTRAINDICATIONS Cupric chloride injection is contraindicated in patients with hypersensitivity to copper (see WARNINGS: Hypersensitivity Reactions ).
Warnings
openFDA Drug LabelingWARNINGS Hepatic Accumulation Copper is primarily eliminated in the bile and excretion is decreased in patients with cholestasis and/or cirrhosis. Hepatic accumulation of copper has been reported in autopsies of patients receiving long-term parenteral nutrition containing copper at dosages higher than recommended. Administration of copper to patients with cholestasis and/or cirrhosis may cause hepatic accumulation of copper. Administration of copper to patients with Wilson disease, an inborn error of copper metabolism with a defect in hepatocellular copper transport, may cause both increased hepatic accumulation of copper and aggravation of the underlying hepatocellular degeneration. For patients with cholestasis, biliary dysfunction, or cirrhosis, monitor hepatic and biliary function during long-term administration of cupric chloride injection. If a patient develops signs or symptoms of hepatobiliary disease during the use of cupric chloride injection, obtain serum concentrations of copper and ceruloplasmin and adjust the dose as indicated (see PRECAUTIONS: Hepatic Impairment ). Hypersensitivity Reactions Post-market safety reporting has identified copper hypersensitivity in women receiving copper-containing intrauterine devices, providing evidence that patients may experience hypersensitivity reactions when exposed to this metal. If hypersensitivity reactions (e.g., pruritis, angioedema, dyspnea, rash, urticaria) occur in patients receiving Cupric Chloride Injection in parenteral nutrition, discontinue the product and initiate appropriate medical treatment (see CONTRAINDICATIONS ). Aluminum Toxicity This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature and they require large amounts of calcium and phosphate solutions, which contain aluminum. Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.
Adverse Reactions
openFDA Drug LabelingADVERSE REACTIONS None known.
Drug Interactions
openFDA Drug LabelingDrug Interactions Cupric ion may degrade ascorbic acid in total parenteral nutrition (TPN) solutions. In order to avoid this loss of ascorbate, multivitamin additives should be added to TPN solutions immediately prior to infusion. Alternatively, the multivitamin additive may be added to one container of TPN solution, followed by copper in a subsequent container.
Description
openFDA Drug LabelingDESCRIPTION Cupric chloride injection USP, 0.4 mg/mL is a sterile, clear, colorless to light blue color, nonpyrogenic solution intended for use as an additive to intravenous solutions for total parenteral nutrition (TPN). Each mL of solution contains 1.07 mg cupric chloride dihydrate; 9 mg sodium chloride and water for injection. The solution contains no bacteriostat, antimicrobial agent or added buffer. The pH is 2.0 (1.5 to 2.5); product may contain hydrochloric acid and sodium hydroxide for pH adjustment. The osmolarity is 0.327 mOsmol/mL (calc.). Cupric chloride, USP is chemically designated cupric chloride, dihydrate. Its molecular weight is 170.48 g/mol. The molecular formula is CuCl 2 • 2H 2 O and the structural formula is: Cupric chloride, USP is a blue to blue-green crystalline compound freely soluble in water, soluble in alcohol and slightly soluble in ether. Sodium chloride, USP is chemically designated NaCl, a white crystalline compound freely soluble in water. The semi-rigid vial is fabricated from a specially formulated polyolefin. It is a copolymer of ethylene and propylene. The small amount of water vapor that can pass through the plastic container wall will not significantly alter the drug concentration. 1
Overdosage
openFDA Drug LabelingOVERDOSAGE Acute copper toxicity has been reported in patients with oral, intravenous, or subcutaneous administration. Clinical manifestations included metallic taste, nausea, vomiting, diarrhea, abdominal pain, neurological signs, such as encephalopathy and multi-organ failure involving kidney, liver, blood and cardiovascular systems, which may be fatal. Chelating agents, such as D-penicillamine, can be used for treatment of acute toxicity. Long-term administration of parenteral copper above the recommended dosage may result in significant accumulation of copper in the liver, brain and other tissues with possible organ damage (see WARNINGS: Hepatic Accumulation ).
How Supplied / Storage and Handling
openFDA Drug LabelingHOW SUPPLIED Cupric Chloride Injection, USP 0.4 mg/mL is supplied as follows: NDC 72603-351-01 10 mL Single-dose glass vial NDC 72603-351-25 Carton of 25 x 10 mL Single-dose glass vials Storage : Store at 20°C to 25°C (68°F to 77°F) [see USP Controlled Room Temperature]. Manufactured for: Northstar Rx LLC Memphis, TN 38141 Manufactured by: Immacule Lifesciences Private Limited Village Thanthewal, Ropar Rd, Nalagarh Solan District, HP 174101, India To report SUSPECTED ADVERSE REACTIONS, contact Northstar Rx LLC at 1-800-206-7821 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch Iss. 07/2024 PI-CUC-00-NS LEIA-311.00 10573
Adverse event reports
Source: openFDA FAERSAttributed to this product's most-reported active ingredient: CUPRIC CHLORIDE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.
Packaging and NDCs
Source: NDC Directory| Package NDC | Product NDC | Labeler | Description | Marketing start |
|---|---|---|---|---|
| 80830-2301-5 | 80830-2301 | Amneal Pharmaceuticals Private Limited | 25 VIAL in 1 CARTON (80830-2301-5) / 10 mL in 1 VIAL (80830-2301-1) | January 29, 2026 |
| 72819-234-16 | 72819-234 | Archis Pharma LLC | 25 VIAL, SINGLE-DOSE in 1 PACKAGE (72819-234-16) / 10 mL in 1 VIAL, SINGLE-DOSE (72819-234-06) | July 5, 2024 |
| 72819-234-99 | 72819-234 | Archis Pharma LLC | 25 VIAL, SINGLE-DOSE in 1 PACKAGE (72819-234-99) / 10 mL in 1 VIAL, SINGLE-DOSE (72819-234-96) | October 1, 2024 |
| 51754-0103-3 | 51754-0103 | Exela Pharma Sciences, LLC | 10 VIAL, SINGLE-DOSE in 1 CARTON (51754-0103-3) / 10 mL in 1 VIAL, SINGLE-DOSE | February 1, 2023 |
| 51754-0103-4 | 51754-0103 | Exela Pharma Sciences, LLC | 25 VIAL, SINGLE-DOSE in 1 CARTON (51754-0103-4) / 10 mL in 1 VIAL, SINGLE-DOSE | February 1, 2023 |
| 72603-351-25 | 72603-351 | Northstar Rx LLC | 25 VIAL, SINGLE-DOSE in 1 PACKAGE (72603-351-25) / 10 mL in 1 VIAL, SINGLE-DOSE (72603-351-01) | October 1, 2024 |
| 84897-013-25 | 84897-013 | Renova Pharmaceuticals LLC | 25 VIAL, SINGLE-DOSE in 1 PACKAGE (84897-013-25) / 10 mL in 1 VIAL, SINGLE-DOSE (84897-013-01) | May 7, 2026 |
| 80830-2301 | 80830-2301 | Amneal Pharmaceuticals Private Limited | — | January 29, 2026 |
| 72819-234 | 72819-234 | Archis Pharma LLC | — | July 5, 2024 |
| 51754-0103 | 51754-0103 | Exela Pharma Sciences, LLC | — | February 1, 2023 |
| 72603-351 | 72603-351 | Northstar Rx LLC | — | October 1, 2024 |
| 84897-013 | 84897-013 | Renova Pharmaceuticals LLC | — | May 7, 2026 |
Sources for this page
| Dataset | Agency | Used for |
|---|---|---|
| NDC Directory | FDA | Identity, ingredients, strengths, forms, routes, labelers, packages |
| Drugs@FDA | FDA | Application, sponsor, submissions, review documents, marketing status |
| Orange Book | FDA | Therapeutic equivalence codes, reference drug flags, patents, exclusivity |
| Drug Labeling | FDA / NLM | Prescribing information reproduced above |
| FAERS | FDA | Adverse event report counts |
Generated September 25, 2026 · 10 sections on this page.